Systemic bioavailability of JAK inhibitor (tofacitinib) and S1P receptor modulator (fingolimod) in topical formulation substantially lower compared to oral equivalents Mean Cmax of tofacitinib 50-fold and 1500-fold lower at Day 1 and 14 of study compared to the lowest commercially available oral alternative Findings from Phase 1b safety portion of study support trial continuation Topline Phase 2a results expected in Q1 2022 BRIDGEWATER, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has completed the Phase 1b portion of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment…

Transaction includes cash payments of $25 million and potential milestones of up to $450 million Sale aligns with VYNE’s strategic plan; proceeds will be used to fund development of Company’s immuno-inflammatory pipeline BRIDGEWATER, N.J., Jan. 13, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has sold its Molecule Stabilizing Technology (MST™) franchise, including AMZEEQ® (minocycline) topical foam, 4%, and ZILXI® (minocycline) topical foam, 1.5%, to Journey Medical Corporation (Nasdaq: DERM) (“Journey”). The sale, which also includes VYNE’s pipeline combination product FCD105, aligns with VYNE’s strategic plan to focus its resources on…

Lead BET Inhibitor Candidate, VYN201, Demonstrates Potent Anti-Inflammatory Effect in Preclinical Studies VYN201 Expected to Enter Clinic in 2022 Phase 2a Results for FMX114 in Mild-to-Moderate Atopic Dermatitis Expected Early Q1 2022 Process for Sale of Topical Minocycline Franchise Continues to Advance Conference call and Live Webcast Today at 8:30 am Eastern Time BRIDGEWATER, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the third quarter ended September 30, 2021 and provided a business update. “The third quarter marks an important turning point for VYNE, as our company is…

BRIDGEWATER, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced preclinical data from a validated animal study showing that its bromodomain and extra-terminal (“BET”) inhibitor, VYN201, demonstrated improvements in reducing fibrotic tissue mass and overall skin repair outcomes with no negative impact on healing time. VYNE is evaluating its lead BET inhibitor, VYN201, for several autoimmune skin diseases that are characterized by lesions, such as chronic ulcers and blisters, which are challenging to treat and can potentially lead to severe infections and surgical intervention. Frequently used treatments for neutrophilic dermatoses are…